Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Common Equity (2019 - 2025)

Historic Common Equity for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $154.4 million.

  • C4 Therapeutics' Common Equity fell 3636.75% to $154.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $154.4 million, marking a year-over-year decrease of 3636.75%. This contributed to the annual value of $216.0 million for FY2024, which is 1224.15% down from last year.
  • Latest data reveals that C4 Therapeutics reported Common Equity of $154.4 million as of Q3 2025, which was down 3636.75% from $174.1 million recorded in Q2 2025.
  • C4 Therapeutics' 5-year Common Equity high stood at $416.4 million for Q2 2021, and its period low was $154.4 million during Q3 2025.
  • Over the past 5 years, C4 Therapeutics' median Common Equity value was $258.3 million (recorded in 2024), while the average stood at $275.3 million.
  • In the last 5 years, C4 Therapeutics' Common Equity skyrocketed by 40831.6% in 2021 and then tumbled by 3636.75% in 2025.
  • Over the past 5 years, C4 Therapeutics' Common Equity (Quarter) stood at $389.6 million in 2021, then dropped by 25.76% to $289.2 million in 2022, then dropped by 14.91% to $246.1 million in 2023, then dropped by 12.24% to $216.0 million in 2024, then dropped by 28.51% to $154.4 million in 2025.
  • Its Common Equity was $154.4 million in Q3 2025, compared to $174.1 million in Q2 2025 and $195.1 million in Q1 2025.